New treatments to protect against radiation damage
Selective Inhibitors of Pro-Ferroptotic Lipoxygenases - Next Generation Radiomitigators
This study is looking at how certain molecules can help protect your cells from damage caused by radiation, especially after treatments like total body irradiation, with the hope of finding new ways to reduce harmful effects and improve recovery for patients like you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10852859 on NIH RePORTER |
What this research studies
This research investigates how certain molecules can help protect cells from damage caused by radiation exposure, particularly after total body irradiation (TBI). The team is exploring the role of specific enzymes and their products in cell death processes, aiming to develop new inhibitors that can mitigate the harmful effects of radiation. By understanding the mechanisms of cell death and inflammation triggered by radiation, the research seeks to identify potential therapeutic strategies to improve patient outcomes. Patients may benefit from these findings if new treatments are developed that can reduce radiation-related injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to radiation, either accidentally or intentionally, and those at risk of such exposure.
Not a fit: Patients who have not been exposed to radiation or are not at risk of exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect patients from the harmful effects of radiation exposure.
How similar studies have performed: Previous research has shown promise in developing radiomitigators, but this approach is exploring novel mechanisms that have not been extensively tested.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Kagan, Valerian E — University of Pittsburgh at Pittsburgh
- Study coordinator: Kagan, Valerian E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.